SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pasquini Marcelo)
 

Sökning: WFRF:(Pasquini Marcelo) > Incidence, Risk Fac...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005797naa a2200613 4500
001oai:DiVA.org:uu-423869
003SwePub
008201110s2020 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:143409431
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4238692 URI
0247 a https://doi.org/10.1111/bjh.164572 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1434094312 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Epperla, Narendranathu Ohio State Univ, James Canc Hosp, Dept Med, Div Hematol, Columbus, OH 43210 USA.;Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.4 aut
2451 0a Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy
264 c 2020-03-02
264 1b WILEY,c 2020
338 a print2 rdacarrier
520 a Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) was conducted including patients receiving allo-HCT between 2008 and 2016, with the primary objective of evaluating the incidence of TA-TMA. Secondary objectives included identification of risk factors associated with TA-TMA, and the impact of TA-TMA on overall survival and the need for renal replacement therapy (RRT). Among 23,665 allo-HCT recipients, the 3-year cumulative incidence of TA-TMA was 3%. Variables independently-associated with increased incidence of TA-TMA included female sex, prior autologous transplant, primary disease (acute lymphoblastic leukaemia and severe aplastic anaemia), donor type (mismatched or unrelated donor), conditioning intensity (myeloablative), GVHD prophylaxis (sirolimus + calcineurin inhibitor), pre-transplant kidney dysfunction and acute GVHD (time-varying effect). TA-TMA was associated with higher mortality (HR = 3 center dot 1, 95% Confidence Interval [CI] = 2 center dot 8-16 center dot 3) and RRT requirement (HR = 7 center dot 1, 95% CI = 5 center dot 7-311 center dot 6). This study provides epidemiologic data on TA-TMA and its impact on transplant outcomes. Increased awareness of the risk factors will enable providers to be vigilant of this uncommon but serious transplant complication. The results will also provide benchmarking for future study designs and comparisons.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a thrombotic microangiopathy
653 a TA-TMA
653 a allogeneic transplantation
653 a allo-HCT
7001 a Li, Angu Univ Washington, Seattle, WA 98195 USA.4 aut
7001 a Logan, Brentu Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.4 aut
7001 a Fretham, Caitrinu Be The Match, Natl Marrow Donor Program, CIBMTR, Minneapolis, MN USA.4 aut
7001 a Chhabra, Saurabhu Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA.4 aut
7001 a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.4 aut
7001 a Chee, Lynetteu Royal Melbourne Hosp City Campus, Victoria, Australia.4 aut
7001 a Copelan, Edwardu Atrium Hlth, Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA.4 aut
7001 a Freytes, Cesar O.u Texas Transplant Inst, San Antonio, TX USA.4 aut
7001 a Hematti, Peimanu Univ Wisconsin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI USA.4 aut
7001 a Lazarus, Hillard M.u Case Western Reserve Univ, Cleveland, OH 44106 USA.4 aut
7001 a Litzow, Marku Mayo Clin Rochester, Div Hematol, Rochester, MN USA.;Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA.4 aut
7001 a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.4 aut0 (Swepub:uu)riols677
7001 a Prestidge, Timu Starship Childrens Hosp, Blood & Canc Ctr, Auckland, New Zealand.4 aut
7001 a Saber, Waelu Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA.4 aut
7001 a Wirk, Baldeepu Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA.4 aut
7001 a Yared, Jean A.u Univ Maryland, Greenebaum Comprehens Canc Ctr, Div Hematol Oncol, Dept Med,Blood & Marrow Transplantat Program, Baltimore, MD 21201 USA.4 aut
7001 a Loren, Alisonu Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.4 aut
7001 a Pasquini, Marcelou Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA.4 aut
7102 a Ohio State Univ, James Canc Hosp, Dept Med, Div Hematol, Columbus, OH 43210 USA.;Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.b Univ Washington, Seattle, WA 98195 USA.4 org
7730 t British Journal of Haematologyd : WILEYg 189:6, s. 1171-1181q 189:6<1171-1181x 0007-1048x 1365-2141
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16457
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423869
8564 8u https://doi.org/10.1111/bjh.16457
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:143409431

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy